Uncertain about the role of novel therapies in retinal vascular diseases? Who you gonna call? Mythbusters! Join our expert faculty as they dispel common myths and misconceptions about dual inhibition therapy and high-dose anti-vascular endothelial growth factor (VEGF) therapy, including those surrounding their durability, effects on disease activity, patient selection, retreatment criteria, and more.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/LOUCRX
- Start Date: 2024-03-25 05:00:00
- End Date: 2024-03-25 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Genentech (Any division) - Amount: 149175.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest